OHSU Team Develops Assay to Help Pick Tyrosine Kinase Inhibitors Against AML | GenomeWeb
The Oregon Health & Science University Cancer Institute is in the early stages of developing an RNAi-based diagnostic designed to help doctors choose what tyrosine kinase inhibitors will work best for certain cases of acute myeloid leukemia.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.